Pharmacopsychiatry 2024; 57(02): 78-81
DOI: 10.1055/a-2262-8297
Letter to the Editor

Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature

1   Department of Pharmacovigilance, University of Sousse, Tunisia
,
Ahlem Ghanmi
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Soumaya Gazzeh
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Bochra Saguem
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Raoudha Slim
1   Department of Pharmacovigilance, University of Sousse, Tunisia
,
Jaafar Nakhli
2   Department of Psychiatry, Farhat Hachad Hospital, Sousse University, Tunisia
,
Chaker Ben Salem
1   Department of Pharmacovigilance, University of Sousse, Tunisia
› Author Affiliations
Zoom Image

Antipsychotics can cause hematologic disorders, and they can have life-threatening consequences. Risperidone, less commonly associated with hematologic adverse effects, is an atypical antipsychotic medication used to treat conditions such as schizophrenia, bipolar disorder and irritability associated with autism. While risperidone primarily affects the central nervous system, it can have some hematologic adverse effects, although these are relatively rare. It is crucial to note that these side effects are not common, and most people taking risperidone do not experience hematologic disorders. The reporting of such disorders may be more frequent with clozapine compared to other atypical antipsychotics because clozapine treatment necessitates regular hematological monitoring [1].



Publication History

Received: 07 January 2024
Received: 01 February 2024

Accepted: 05 February 2024

Article published online:
12 March 2024

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany